Neumonía por Pneumocystis jirovecii en pacientes sin infección por VIH

Pneumocystis jirovecii pneumonia in non-HIV-infected patients

Contenido principal del artículo

Jaime Andrés Alvarado, MD.
Jacqueline Pavía, MD.
Mónica Caicedo, MD.
María Ximena Chacón, MD.
Bibiana Pinzón, MD.
Margarita Baldión, MD.

Resumen

La neumonía por Pneumocystis jirovecii es una entidad relativamente infrecuente por fuera del contexto de la infección por virus de inmunodeficiencia humana (VIH). No obstante, se espera un aumento en su incidencia en pacientes con otras causas de compromiso secundario de la inmunidad sobre todo teniendo en cuenta la proliferación de procedimientos relacionados con trasplante de órganos y la disponibilidad creciente de medicamentos inmunosupresores. La presentación clínica y radiológica es diferente a la reportada usualmente en pacientes con SIDA. La evolución es más agresiva y su pronóstico más oscuro.

Palabras clave:

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Biografía del autor/a (VER)

Jaime Andrés Alvarado, MD., Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Neumólogo, Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Jacqueline Pavía, MD., Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Neumólogo, Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Mónica Caicedo, MD., Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Neumólogo, Fundación Santa Fe de Bogotá. Bogotá, Colombia.

María Ximena Chacón, MD., Universidad El Bosque. Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Residente de Medicina Interna, Universidad El Bosque. Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Bibiana Pinzón, MD., Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Radióloga, Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Margarita Baldión, MD., Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Patóloga, Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Referencias (VER)

Álvarez F, Bandi V, Stager C, Guntupalli KK. Detection of Pneumocystis carinii in tracheal aspirates of intubated patients using calcofluor-white (Fungi-Fluor) and immunofluorescence antibody (Genetic Systems) stains. Crit Care Med. 1997; 25: 948–952.

Thomas CF, Jr., Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004; 350: 2487-2498.

Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non HIV patients and prognostic factors including microbiological genotypes.4. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis. 2001; 33: 1397-405.

Damiani C, Le Gal S, Lejeune D, et al. Serum (1->3)-beta-D-glucan levels in primary infection and pulmonary colonization with Pneumocystis jirovecii. J Clin Microbiol. 2011; 49: 2000–2002.

Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother. 2012; 18: 793-806.

Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest. 1997; 99: 2110–2117.

Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol. 2000; 164: 3755–3763.

Benfield TL, Vestbo J, Junge J, Nielsen TL, Jensen AB, Lundgren JD. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 1995; 151: 1058–1062.

Toper C, Rivaud E, Daniel C, Cerf C, Parquin F, Catherinot E, et al. Pneumocystis jirovecii pneumonia in non-HIV infected patients: a study of 41 cases. Rev Pneumol Clin. 2011; 67: 191-198.

ReidAB, ChenSC, WorthLJ. Pneumocystis jirovecii pneumonia in non-HIV infected patients: new risks and diagnostic tools. Curr Opin Infect Dis. 2011; 24: 534-44.

Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant. 2009; 9: S227-33.

Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992; 267: 832–837.

Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener’s granulomatosis. Am J Respir Crit Care Med. 1995; 151: 795–799.

Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999; 42: 780–789.

Krajicek BJ, Thomas CF Jr, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis and treatment. Clin Chest Med. 2009; 30: 265-278.

Komano Y, Harigai M, Koike R, et al. Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009; 61: 305–312.

www.pneumotox.org

Toper C, Rivaud E, Daniel C, Cerf C, Parquin F, Catherinot E, Honderlick P, et al Pneumocystis jirovecii pneumonia in non-HIV infected patients: a study of 41 cases. Rev Pneumol Clin. 2011; 67: 191-198.

Ainoda Y, Hirai Y, Fujita T, Isoda N, Totsuka K; Analysis of clinical features of non HIV Pneumocystis jirovecii pneumonia. J Infect Chemother. 2012;18:722-728.

Drewes J, Labra W A, Tenorio J. Neumonía por Pneumocystis: reporte de un caso de evolución fulminante y actualización de su etiologia. Rev Chil Rad. 2004; 10: 172-175.

Catherinot E, Lanternier F, Bougnoux ME, et al. Pneumocystis jirovecii pneumonia Infect Dis Clin N Am. 2010; 24: 107–138.

de Oliveira A, Unnasch TR, Crothers K, et al. Performance of a molecular viability assay for the diagnosis of Pneumocystis pneumonia in HIV-infected patients. Diagn Microbiol Infect Dis.2007; 57: 169–76.

Mühlethaler K, Bögli-Stuber K, Wasmer S, von Garnier C, Dumont P, Rauch A, et al. Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients. Eur Respir J. 2012; 39: 971-8.

Larsen HH, Huang L, Kovacs JA, et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV infected patients. J Infect Dis. 2004; 189: 1679–83.

Held J, Koch MS, Reischl U, et al. Serum (1 –> 3)-beta-D-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin Microbiol Infect. 2011; 17: 595–602.

Marty FM, Koo S, Bryar J, Baden LR. (1->3)beta-D-Glucan assay positivity in patients with Pneumocystis (carinii) jirovecii pneumonia. Ann Intern Med. 2007; 147: 70–72.

Moon SM, Kim T, Sung H, et al. Outcomes of moderate to severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother. 2011; 55:4613-8.

De Castro N, Pavie J, Lagrange-Xélot M, Molina JM. Pneumocystose chez les patients d’onco-hématologie : est-ce inévitable?; Revue des Maladies Respiratoires. 2007; 24: 741-750.

Citado por